Keytruda (Pembrolizumab) Receives Initial FDA Approval as New Molecular Entity

The U.S. Food and Drug Administration (FDA) granted initial approval to Keytruda (pembrolizumab) on September 4, 2014. This landmark approval introduced pembrolizumab as a Type 1 New Molecular Entity, signifying a novel active ingredient entering the market. The drug's sponsor is Merck Sharp Dohme.

Background

Pembrolizumab, known by its brand name Keytruda, received its initial FDA approval as a Type 1 New Molecular Entity. This classification is assigned to drugs containing an active ingredient that has never before been approved by the FDA. The approval on September 4, 2014, marked the first time pembrolizumab became available as a therapeutic option in the United States. As a New Molecular Entity, it represents a distinct chemical structure or biological product, differentiating it from existing approved drugs and often indicating a new mechanism of action or a significant advancement in treatment.

What this means

The initial FDA approval of Keytruda (pembrolizumab) on September 4, 2014, was a pivotal event for oncology and for its sponsor, Merck Sharp Dohme. As a Type 1 New Molecular Entity, Keytruda entered the therapeutic landscape as a completely new drug, rather than a modification or new formulation of an already approved substance. This designation typically implies that the drug offers a novel approach to treatment or addresses an unmet medical need. The approval process for a New Molecular Entity is rigorous, involving extensive clinical trials to demonstrate safety and efficacy. While the specific initial indication for which Keytruda was approved is not detailed in the provided data, its introduction as a New Molecular Entity laid the groundwork for its subsequent impact on various cancer treatments.

Source

The details regarding the initial FDA approval of Keytruda (pembrolizumab) were sourced from the official U.S. Food and Drug Administration (FDA) database. The approval for Biologics License Application (BLA) BLA 125514 was officially recorded on 2014-09-04 and can be verified through accessdata.fda.gov.